Table 2.

Clinical and donor characteristics of all study patients for thrombosis groups

Total, n=232No thrombosis, n=206With thrombosis, n=26p-value
MELD score, median (IQR)15 (10–20)15 (10–19)18 (12–26.5)0.056
Primary hepatic carcinoma, n (%)73 (31.5)69 (33.5)4 (15.4)0.061
Hemoglobin, g/L, mean (SD)109.3 (24.4)111 (24)96.4 (23.9)0.007
RBC count, × 1012/L, median (IQR)3.5 (3–4.1)3.5 (3.0–4.2)3.1 (2.6–3.5)0.017
Haematocrit, %, median (IQR)32 (27.9–37.5)32.4 (28.2–38.1)28.3 (23.8–33)0.006
PT, seconds, median (IQR)17.7 (15.7–20.9)17.6 (15.5–20.5)19.6 (17.1–27.8)0.004
aPTT, seconds, median (IQR)44.8 (40.2–51.4)44.4 (39.9–50.4)48.3 (42.5–58.1)0.031
INR, median (IQR)1.5 (1.3–1.8)1.5 (1.2–1.8)1.7 (1.4–2.6)0.004
Fibrinogen, g/L, median (IQR)1.8 (1.5–2.4)1.8 (1.5–2.4)1.6 (1–2)0.008
D-dimer, mg/L, median (IQR)1.8 (0.8–4.3)1.7 (0.7–4.1)3.6 (1.3–10.1)0.004
  • aPTT = activated partial thromboplastin time; INR = international normalised ratio; MELD = Model for End-stage Liver Disease; PT = prothrombin time; RBC = red blood cell.